Table 6

Proportion of patients receiving besifovir 90 or 150 mg daily with carnitine (normal 34–78 µmol/L) and phosphorus drug toxicity

PhosphorusBesifovir 90 mgBesifovir 150 mg
Week of follow-upI (%)II (%)III (%)IV (%)Week of follow-upI (%)II (%)III (%)IV (%)
2 (n=34)1 (2.94)0 (0.00)0 (0.00)0 (0.00)2 (n=39)2 (5.13)0 (0.00)0 (0.00)0 (0.00)
4 (n=36)1 (2.78)0 (0.00)0 (0.00)0 (0.00)4 (n=38)1 (2.63)0 (0.00)0 (0.00)0 (0.00)
8 (n=36)2 (5.56)0 (0.00)0 (0.00)0 (0.00)8 (n=38)0 (0.00)0 (0.00)0 (0.00)0 (0.00)
12 (n=36)0 (0.00)0 (0.00)0 (0.00)0 (0.00)12 (n=38)2 (5.26)0 (0.00)0 (0.00)0 (0.00)
16 (n=36)0 (0.00)1 (2.78)0 (0.00)0 (0.00)16 (n=38)2 (5.26)0 (0.00)0 (0.00)0 (0.00)
20 (n=35)2 (5.71)0 (0.00)0 (0.00)0 (0.00)20 (n=37)1 (2.70)0 (0.00)0 (0.00)0 (0.00)
24 (n=35)2 (5.71)0 (0.00)0 (0.00)0 (0.00)24 (n=38)1 (2.63)0 (0.00)0 (0.00)0 (0.00)
32 (n=34)3 (8.82)0 (0.00)0 (0.00)0 (0.00)32 (n=38)1 (2.63)1 (2.63)0 (0.00)0 (0.00)
40 (n=34)1 (2.94)0 (0.00)0 (0.00)0 (0.00)40 (n=38)0 (0.00)0 (0.00)0 (0.00)0 (0.00)
48 (n=34)0 (0.00)0 (0.00)0 (0.00)0 (0.00)48 (n=38)2 (5.26)0 (0.00)0 (0.00)0 (0.00)
CarnitineBesifovir 90 mgBesifovir 150 mg
Week of follow-upLowNormalHighWeek of follow-upLowNormalHigh
2 (n=35)6 (17.14)29 (82.86)0 (0.00)2 (n=39)14 (35.90)25 (64.10)0 (0.00)
4 (n=36)10 (27.78)26 (72.22)0 (0.00)4 (n=38)20 (52.63)18 (47.37)0 (0.00)
8 (n=36)10 (27.78)26 (72.22)0 (0.00)8 (n=38)17 (44.74)20 (52.63)1 (2.63)
12 (n=36)3 (8.33)32 (88.89)1 (2.78)12 (n=38)6 (15.79)30 (78.95)2 (5.26)
16 (n=36)3 (8.33)31 (94.44)2 (5.56)16 (n=38)6 (15.79)31 (81.58)1 (2.63)
20 (n=35)7 (20.00)28 (80.00)0 (0.00)20 (n=37)11 (29.73)26 (70.27)0 (0.00)
24 (n=35)2 (5.71)33 (94.29)0 (0.00)24 (n=38)11 (28.95)26 (68.42)1 (2.63)
32 (n=34)2 (5.88)32 (94.12)0 (0.00)32 (n=38)12 (31.58)25 (65.79)1 (2.63)
40 (n=34)3 (8.82)31 (91.18)0 (0.00)40 (n=38)7 (18.42)31 (81.58)0 (0.00)
48 (n=34)8 (23.53)26 (76.47)0 (0.00)48 (n=38)3 (7.89)33 (86.84)2 (5.26)